Immunisation with foamy virus Bet fusion proteins as novel strategy
Transcrição
Immunisation with foamy virus Bet fusion proteins as novel strategy
Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery. Immunologic Research, M. Mühle, K. Hoffmann, M. Löchelt, J. Denner Online Resource 2 2F5/Bet-E1 Response [RU] 250 200 150 25 100 0 -200 0 Response [RU] 200 400 600 800 1000 1200 1400 2F5/Bet-E2 250 50 200 150 100 25 12.5 50 KD = 4.3 nM 0 -50 -200 0 200 400 600 800 1000 1200 1400 2F5/Bet-E1+Bet-E2 200 Response [RU] 100 50 -50 150 50 100 25 12.5 50 0 -50 KD = 5.9 nM -200 0 200 400 600 800 1000 1200 1400 2F5/Bet-E1-E2 Response [RU] 250 200 150 100 50 0 -50 -100 25 250 200 150 100 50 0 -50 -100 -150 -200 100 50 KD = 19 nM -500 Response [RU] 50 Surface plasmon resonance experiments with the antigens used for immunisation and the antibodies 2F5 and 4E10. The signal intensity in response units (RU), the protein concentrations (in nM), protein and buffer injection points (black and grey arrows) and calculated KD values are indicated for interactions measured with captured 2F5 antibody and Bet-E1, Bet-E2, Bet-E1+ Bet-E2 and Bet-E1-E2 or for interaction measured with captured 4E10 antibody and the Bet-E1-E2 antigen. Response curves are shown as grey lines, fitted curves are in black. Note that response peaks between individual injections (arrows) correspond to bulk contributions as a result of differences in the buffer composition 0 500 1000 1500 2000 4E10/Bet-E1-E2 100 200 400 KD = 224 nM 0 200 400 600 800 1000 1200 1400 Time [s] correspondence to: [email protected], Robert Koch Institute, Center for HIV and Retrovirology, Berlin, Nordufer 20, 13553 Germany
Documentos relacionados
An overview of current pharmacy impact on immunisation
impact on immunisation A global report 2016. The Hague: International Pharmaceutical Federation; 2016.
Leia maisEVALUATION OF PROPHYLACTIC EFFICACY OF HUMAN ANTI
established. It is recognized that high production potential is not achieved either with murine hybridomas or with mouse-human heterohybrid cell line (22.Hanlon et.al. 2001). Cost-effective product...
Leia mais